All In Biotech

NDA 214200 · Pharmacosmos

Cosela

Trilaciclib Dihydrochloride · Intravenous

NovelBreakthrough therapyPriority review

CDER novel approval, Feb 12, 2021: To mitigate chemotherapy-induced myelosuppression in small cell lung cancer

Last checked: Nov 20, 2026Latest source record: Aug 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Feb 12, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

0 Phase 3, 0 recruiting

FAERS reports

244

136 serious, 25 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2025.

COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). COSELA is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. ( 1 )

Mechanism: Trilaciclib is a transient inhibitor of CDK 4 and 6. Hematopoietic stem and progenitor cells (HSPCs) in the bone marrow give rise to circulating neutrophils, RBCs, and platelets. HSPC proliferation is dependent on CDK4/6 activity.

Therapeutic areas: Oncology · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 12, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
  • COSELA · TRILACICLIB DIHYDROCHLORIDE EQ 300MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trilaciclib Dihydrochloride" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myelosuppression37
  • off label use27
  • dyspnoea19
  • white blood cell count decreased19
  • platelet count decreased18
  • death16
  • pneumonia15
  • anaemia14
  • performance status decreased14
  • fatigue13
  • nausea13
  • infection12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
202128
202267
202363
202418
202550
202617

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cosela (Trilaciclib Dihydrochloride)

2024 spending

$99K

Beneficiaries

n/a

12 claims

Per beneficiary

n/a

$1,552.09 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$80,223
2024$99,334

Part B: Cosela (Trilaciclib Dihydrochloride) · HCPCS J1448

2024 spending

$20.3M

Beneficiaries

797

6,219 claims

Per beneficiary

$25,532

2024 ASP limit $5.28 per unit

View as table
YearSpending
2020$0
2021$1,710,573
2022$12,092,253
2023$17,240,563
2024$20,349,383

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Pharmacosmos

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.